文献速递结核与非结核分枝杆菌

改良全口服9个月方案治疗耐利福平结核病的有效性与安全性:前瞻性队列研究

Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
PubMed 文献 · Lancet Infect Dis · 2024-06-13

这项多国前瞻性单臂队列研究在WHO欧洲区域13个国家评估了三种改良全口服9个月方案治疗氟喹诺酮敏感耐利福平肺结核的有效性和安全性,共纳入2636例治疗队列患者,治疗成功2181例(82.7%),22个月时无不良结局的累积概率为79%(95%CI 78-81),安全性队列2813例中252例(9.0%)发生301起关注的不良事件。

要点

  • 改良全口服9个月方案治疗成功2181例(82.7%),22个月无不良结局累积概率79%(95%CI 78-81)。
  • 安全性队列2813例中252例(9.0%)发生301起关注的不良事件,最常见为骨髓抑制139例(4.9%)。
  • 年龄>64岁、HIV阳性、双侧空洞、吸烟史、基线贫血、失业、基线肝酶升高和过量饮酒与不良结局正相关。

核心结论

  • 高治疗成功率和良好的安全性结果表明,改良全口服9个月方案在规划条件下具有相当大的应用潜力,尤其适用于不符合当前WHO推荐6个月方案条件的个体以及需要替代方案的地区。

研究设计与样本

  • 多国、前瞻性、单臂队列研究,2020-23年在WHO欧洲区域13个国家评估改良全口服9个月方案治疗氟喹诺酮敏感耐利福平肺结核的有效性和安全性。
  • 纳入成人及所有年龄儿童,经细菌学确诊的耐利福平、氟喹诺酮敏感肺结核,以及0-18岁临床诊断且确认接触耐利福平、氟喹诺酮敏感结核的儿童。
  • 6岁及以上参与者接受两种方案之一:贝达喹啉、利奈唑胺、左氧氟沙星、氯法齐明和环丝氨酸;或贝达喹啉、利奈唑胺、左氧氟沙星、氯法齐明和德拉马尼。
  • 6岁以下儿童接受德拉马尼、利奈唑胺、左氧氟沙星和氯法齐明。
  • 成功完成治疗后随访12个月以检测复发和死亡;治疗队列2636例,安全性队列2813例(至少接受一剂)。

主要发现

  • 2020年8月28日至2021年5月26日筛查7272例患者,2636例纳入治疗队列;1966例(74.6%)为男性,670例(25.4%)为女性,中位年龄43岁(IQR 33-53)。
  • 治疗成功记录于2181例(82.7%)参与者;治疗开始后22个月无不良研究结局的累积概率为79%(95%CI 78-81)。
  • 年龄>64岁 vs 35-44岁(调整后风险比2.61 [95%CI 1.70-4.04])、HIV阳性(1.53 [1.16-2.01])、双侧空洞(1.68 [1.29-2.19])、吸烟史(1.34 [1.05-1.71])、基线贫血(1.46 [1.15-1.86])、失业(1.37 [1.04-1.80])、基线肝酶升高(1.40 [1.13-1.73])和过量饮酒(1.47 [1.14-1.89])与不良研究结局正相关。
  • 安全性队列2813例中,252例(9.0%)参与者记录到301起关注的不良事件,最常见为骨髓抑制(139例[4.9%]参与者,157起[52.2%]事件)。

关键数值与推荐

  • 主要结局为研究随访22个月前未发生不良研究结局(治疗失败、治疗中失访、死亡或复发)的累积概率。
  • 主要安全性结局为治疗期间每个关注的不良事件(周围神经病变、视神经炎、骨髓抑制、肝炎、QT间期延长、低钾血症和急性肾损伤)3级或以上严重程度的发生率。

临床怎么用

  • 作者认为,高治疗成功率和良好的安全性结果表明改良全口服9个月方案在规划条件下具有相当大的应用潜力,尤其适用于不符合当前WHO推荐6个月方案条件的个体以及需要替代方案的地区。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2020, WHO guidelines prioritised the use of a standard fully oral short treatment regimen (STR) consisting of bedaquiline, levofloxacin or moxifloxacin, ethionamide, ethambutol, high-dose isoniazid, pyrazinamide, and clofazimine for the management of rifampicin-resistant tuberculosis. A high prevalence of resistance to constituent drugs precluded its widespread use by countries in the WHO European region. We evaluated three 9-month fully oral modified STRs (mSTRs) in which ethionamide, ethambutol, isoniazid, and pyrazinamide were replaced by linezolid, cycloserine, or delamanid (or a combination). METHODS: This multicountry, prospective, single-arm, cohort study examined the effectiveness and safety of mSTRs for fluoroquinolone-susceptible, rifampicin-resistant pulmonary tuberculosis in 13 countries in the WHO European region during 2020-23. We enrolled adults and children of all ages with bacteriologically confirmed rifampicin-resistant, fluoroquinolone-susceptible pulmonary tuberculosis, and children (aged 0-18 years) with clinically diagnosed disease and a confirmed contact with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis. Participants aged 6 years or older received one of two regimens: bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine; or bedaquiline, linezolid, levofloxacin, clofazimine, and delamanid. Children younger than 6 years received delamanid, linezolid, levofloxacin, and clofazimine. Participants were followed up for 12 months after successful treatment completion to detect recurrence and death. The primary outcome was the cumulative probability of not having an unsuccessful study outcome (defined as treatment failure, on-treatment loss to follow-up, death, or recurrence) before 22 months of study follow-up. The primary safety outcome was the incidence of each adverse event of interest (peripheral neuropathy, optic neuritis, myelosuppression, hepatitis, prolonged QT interval, hypokalaemia, and acute kidney injury) of grade 3 or higher severity during the treatment course. FINDINGS: Between Aug 28, 2020 and May 26, 2021, 7272 patients were screened and 2636 were included in the treatment cohort. 1966 (74·6%) were male, 670 (25·4%) were female, and median age was 43 years (IQR 33-53). Treatment success was recorded for 2181 (82·7%) participants. The cumulative probability of not having an unsuccessful study outcome 22 months after treatment initiation was 79% (95% CI 78-81). Increasing age (adjusted hazard ratio 2·61 [95% CI 1·70-4·04] for people aged >64 years vs 35-44 years), HIV-positive status (1·53 [1·16-2·01]), presence of bilateral cavities (1·68 [1·29-2·19]), smoking history (1·34 [1·05-1·71]), baseline anaemia (1·46 [1·15-1·86]), unemployment (1·37 [1·04-1·80]), elevated baseline liver enzymes (1·40 [1·13-1·73]), and excessive alcohol use (1·47 [1·14-1·89]) were positively associated with unsuccessful study outcomes. In the safety cohort of 2813 participants who received at least one dose, 301 adverse events of interest were recorded in 252 (9·0%) participants with the most frequent being myelosuppression (139 [4·9%] participants, 157 [52·2%] events). INTERPRETATION: The high treatment success and good safety results indicate considerable potential for the use of mSTRs in programmatic conditions, especially for individuals not eligible for the current WHO-recommended 6-month regimen and in settings with a need for alternative options. FUNDING: The Global Fund to Fight AIDS, Tuberculosis and Malaria; United States Agency for International Development; Government of Germany; and WHO. TRANSLATION: For the Russian translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Korotych O, Achar J, Gurbanova E, et al. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study. Lancet Infect Dis. 2024. PMID: 38880112. doi:10.1016/S1473-3099(24)00228-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。